Medications

Mivavotinib for relapsed/refractory B-cell lymphoma

In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for ...

Oncology & Cancer

Lymphoma mutation yields super-competitive immune cells

The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells, according to a multi-institutional ...

Oncology & Cancer

Military probing whether cancers linked to nuclear silo work

Nine military officers who had worked decades ago at a nuclear missile base in Montana have been diagnosed with blood cancer and there are "indications" the disease may be linked to their service, according to military briefing ...

page 6 from 40